| Revenue Growth | Recorlev up 93% to $71.5M; Gvoke down 14% to $21.7M; Keveyis up 9%. |
|---|---|
| Mgmt Confidence | Extremely high; described trajectory as a 'new growth curve' and 'spectacular'. |
| Demand Visibility | Record referrals and new patient starts for Recorlev; Gvoke prescriptions up 20% sequentially. |
| Margin Trends | Gross margin improved to 88% from 85% due to favorable product mix. |
| Op. Leverage | Adjusted EBITDA grew 77% to $30.8M, outstripping 44% revenue growth. |
| Vol vs Price | Volume-led; Gvoke prescriptions grew 5% YoY despite revenue decline from adjustments. |
| Segment Growth | Recorlev is the primary driver; Keveyis delivered fourth consecutive growth quarter. |
| New Clients | Record number of new referrals and new patient starts in Q3. |
| Capex & Debt | Prioritizing commercial investment and XP-8121 pipeline over M&A for now. |
| Regulatory | Initiating XP-8121 Phase 3 Cornerstone study by year-end 2026. |
| Commentary | Shifted from 'build to yield' phase following January commercial team expansion. |
| New Launches | XP-8121 Phase 3 launch imminent; potential commercial launch in 2030. |
Growth
Total revenue grew 44% to $107.2M; Recorlev revenue surged 93% to $71.5M.
Outlook
Raised 2030 revenue outlook to $1B+; Recorlev $1B annual target accelerated by 3-4 years.
Risks
Gvoke faced a $4M one-time Medicaid gross-to-net adjustment; Recorlev access remains restricted by prior authorizations.
The company's earnings call, NASDAQ: XERS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Xeris Biopharma Holdings, Inc.: key numbers
- Share price
- $16.70Close, Nov 16
- Market cap
- $3.05B
- Shares outstanding
- 182.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xeris Biopharma Holdings, Inc.
All →Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock
Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).
- Value
- $312K
- Shares
- 25,000
- Price
- $12.49
- Holding change
- -1.6%
- Trade date
- Nov 5, 2026
Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY
Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.
- Key figure
- Net income $11.3M · +1718.0% YoY
Xeris Biopharma Holdings Financial Results
Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.
“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”
John Shannon, Chairman and Chief Executive Officer
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
John Shannon, Chairman and Chief Executive Officer
Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock
Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).
- Value
- $51.2K
- Shares
- 5,000
- Price
- $10.23
- Holding change
- -0.4%
- Trade date
- Nov 2, 2026
Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock
Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).
- Value
- $256K
- Shares
- 25,000
- Price
- $10.23
- Holding change
- -2.2%
- Trade date
- Nov 2, 2026
Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock
Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).
- Value
- $153K
- Shares
- 15,000
- Price
- $10.23
- Holding change
- -0.9%
- Trade date
- Nov 2, 2026